EZH2 and chronic myelogenous leukemia, BCR-ABL1 positive: The role of EZH2 in CML remains unclear, and unlike other myeloid malignancies, inactivating mutations of EZH2 are rare in CML, although the upregulation of EZH2 can result in a form of myeloproliferative disease [34].